Posted On: 12/26/2013 8:26:43 PM
Post# of 7769
U.S. Scrips signed an exclusive distribution deal in the U.S. for RapiMeds with DPG (www.dpgdistribution.com), which is experienced at getting products on the shelves of large retailers and pharmacies, including Walmart, Target, Cosco, Walgreens, CVS, and more.
It also signed a similar deal with Forbes in Hong Kong for the exclusive rights to sell and distribute RapiMeds in China. I understand Scrips's sales team recently returned from a trip to China, and I am expecting some good news from that trip soon. Indeed, according to a recent PR, Forbes had identified over 300 pharmacies and hospitals for the potential sales of RapiMeds in China. For more details on the China opportunity, please visit http://scripsamerica.com/wp-content/uploads/2...ackage.pdf . Frankly, the potential numbers associated with a successful marketing launch in China are difficult to fathom, they could be astronomical. There are no children's tylenol fast melt tablets in China, and I see no reason why Scrips and Forbes cannot be first to market there. Since my last post, here is what Bob and his team had to say about China: ScripsAmerica November 25 PR updating shareholders on recent China visit: http://finance.yahoo.com/news/scripsamerica-m...00734.html
So, assuming no delays with the 60- to 90-day product registration approval process, which I'm certain Forbes is helping with, I fully expect purchase orders from China no later than February. So it appears China will win the race to the shelves.
It also signed a similar deal with Forbes in Hong Kong for the exclusive rights to sell and distribute RapiMeds in China. I understand Scrips's sales team recently returned from a trip to China, and I am expecting some good news from that trip soon. Indeed, according to a recent PR, Forbes had identified over 300 pharmacies and hospitals for the potential sales of RapiMeds in China. For more details on the China opportunity, please visit http://scripsamerica.com/wp-content/uploads/2...ackage.pdf . Frankly, the potential numbers associated with a successful marketing launch in China are difficult to fathom, they could be astronomical. There are no children's tylenol fast melt tablets in China, and I see no reason why Scrips and Forbes cannot be first to market there. Since my last post, here is what Bob and his team had to say about China: ScripsAmerica November 25 PR updating shareholders on recent China visit: http://finance.yahoo.com/news/scripsamerica-m...00734.html
So, assuming no delays with the 60- to 90-day product registration approval process, which I'm certain Forbes is helping with, I fully expect purchase orders from China no later than February. So it appears China will win the race to the shelves.
(0)
(0)Scroll down for more posts ▼
